Ebola virus disease candidate vaccines under evaluation in clinical trials

References

• Kuhn JH. Ebolavirus and Marburgvirus infections. In: Kasper DL, Fauci AS, Hauser SL, et al., editors. Harrison’s principles of internal medicine. Columbus (OH): McGraw-Hill Education; 2015. p. 1323–1329.
   Google Scholar
• Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med. 2004;10(12 Suppl):S110–S121.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Ebola situation report [Internet]. 2016 [cited 2016 Mar 30]. Available from: http://apps.who.int/ebola/current-situation/ebola-situation-report-30-march-2016.
   Google Scholar
• Yang ZY, Duckers HJ, Sullivan NJ, et al. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med. 2000;6(8):886–889.
   PubMed Web of Science ®Google Scholar
• Hanson RP. The natural history of vesicular stomatitis. Bacteriol Rev. 1952;16(3):179–204.
   PubMedGoogle Scholar
• Huang AS, Wagner RR. Comparative sedimentation coefficients of RNA extracted from plaque-forming and defective particles of vesicular stomatitis virus. J Mol Biol. 1966;22(2):381–384.
   PubMed Web of Science ®Google Scholar
• Prevec L, Whitmore GF. Purification of vesicular stomatitis virus and the analysis of P32-labeled viral components. Virology. 1963;20:464–471.
   PubMed Web of Science ®Google Scholar
• Ball LA, White CN. Order of transcription of genes of vesicular stomatitis virus. Proc Natl Acad Sci U S A. 1976;73(2):442–446.
   PubMed Web of Science ®Google Scholar
• Lawson ND, Stillman EA, Whitt MA, et al. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A. 1995;92(10):4477–4481.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011;204(Suppl 3):S1075–S1081.
   PubMed Web of Science ®Google Scholar
• Clarke DK, Nasar F, Lee M, et al. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol. 2007;81(4):2056–2064.
   PubMed Web of Science ®Google Scholar
• Jones SM, Feldmann H, Ströher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11(7):786–790.
   PubMed Web of Science ®Google Scholar
• Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004;78(10):5458–5465.
   PubMed Web of Science ®Google Scholar
• Medaglini D, Harandi AM, Ottenhoff THM, et al. Ebola vaccine R&D: filling the knowledge gaps. Sci Transl Med. 2015;7(317):317ps324.
   Web of Science ®Google Scholar
• Martinez I, Rodriguez LL, Jimenez C, et al. Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host. J Virol. 2003;77(14):8039–8047.
   PubMed Web of Science ®Google Scholar
• Publicover J, Ramsburg E, Rose JK. Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J Virol. 2004;78(17):9317–9324.
   PubMed Web of Science ®Google Scholar
• Kennedy SB, Neaton JD, Lane HC, et al. Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: design, procedures, and challenges. Clin Trials. 2016;13(1):49–56.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386(9996):857–866.
   PubMed Web of Science ®Google Scholar
• Huttner A, Dayer J-A, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15(10):1156–1166.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008;4(11):e1000225.
   PubMed Web of Science ®Google Scholar
• Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine - preliminary report. N Engl J Med. 2015. doi:10.1056/NEJMoa1414216. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med. 2015;374(17):1647–1660.
   Web of Science ®Google Scholar
• Mire CE, Matassov D, Geisbert JB, et al. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature. 2015;520(7549):688–691.
   PubMed Web of Science ®Google Scholar
• Cooper D, Wright KJ, Calderon PC, et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol. 2008;82(1):207–219.
   PubMed Web of Science ®Google Scholar
• Skiadopoulos MH, Surman SR, Riggs JM, et al. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. Virology. 2002;297(1):136–152.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Skiadopoulos MH, McAuliffe JM, et al. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J Virol. 2000;74(15):6821–6831.
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Camargo E, Collins PL. Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. J Virol. 1996;70(10):6634–6641.
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Marzi A, Feldmann F, et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology. 2009;383(2):348–361.
   PubMed Web of Science ®Google Scholar
• DiNapoli JM, Yang L, Samal SK, et al. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine. 2010;29(1):17–25.
   PubMed Web of Science ®Google Scholar
• Yang L, Sanchez A, Ward JM, et al. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology. 2008;377(2):255–264.
   PubMed Web of Science ®Google Scholar
• Bukreyev AA, Dinapoli JM, Yang L, et al. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology. 2010;399(2):290–298.
   PubMed Web of Science ®Google Scholar
• Meyer M, Garron T, Lubaki NM, et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest. 2015;125(8):3241–3255.
   PubMed Web of Science ®Google Scholar
• Tatsis N, Ertl HCJ. Adenoviruses as vaccine vectors. Mol Ther. 2004;10(4):616–629.
   PubMed Web of Science ®Google Scholar
• Chen H, Xiang ZQ, Li Y, et al. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol. 2010;84(20):10522–10532.
   PubMed Web of Science ®Google Scholar
• Ondondo BO. The influence of delivery vectors on HIV vaccine efficacy. Front Microbiol. 2014;5:439.
   PubMed Web of Science ®Google Scholar
• Lasaro MO, Ertl HCJ. New insights on adenovirus as vaccine vectors. Mol Ther. 2009;17(8):1333–1339.
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–1893.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010;29(2):304–313.
   PubMed Web of Science ®Google Scholar
• McCoy K, Tatsis N, Korioth-Schmitz B, et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol. 2007;81(12):6594–6604.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011;85(9):4222–4233.
   PubMed Web of Science ®Google Scholar
• Abbink P, Lemckert AAC, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007;81(9):4654–4663.
   PubMed Web of Science ®Google Scholar
• Xiang ZQ, Gao GP, Reyes-Sandoval A, et al. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol. 2003;77(20):10780–10789.
   PubMed Web of Science ®Google Scholar
• Tucker SN, Tingley DW, Scallan CD. Oral adenoviral-based vaccines: historical perspective and future opportunity. Expert Rev Vaccines. 2008;7(1):25–31.
   PubMed Web of Science ®Google Scholar
• Deal C, Pekosz A, Ketner G. Prospects for oral replicating adenovirus-vectored vaccines. Vaccine. 2013;31(32):3236–3243.
   PubMed Web of Science ®Google Scholar
• Richardson JS, Pillet S, Bello AJ, et al. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol. 2013;87(7):3668–3677.
   PubMed Web of Science ®Google Scholar
• Vogels R, Zuijdgeest D, Van Rijnsoever R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 2003;77(15):8263–8271.
   PubMed Web of Science ®Google Scholar
• Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010;28(4):950–957.
   PubMed Web of Science ®Google Scholar
• Sridhar S. Clinical development of Ebola vaccines. Ther Adv Vaccines. 2015;3(5–6):125–138.
   PubMedGoogle Scholar
• Sullivan NJ, Sanchez A, Rollin PE, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000;408(6812):605–609.
   PubMed Web of Science ®Google Scholar
• Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4(115):115ra111.
   Web of Science ®Google Scholar
• Herath S, Le Heron A, Colloca S, et al. Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen. Vaccine. 2015;33(51):7283–7289.
   PubMed Web of Science ®Google Scholar
• Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20(10):1126–1129.
   PubMed Web of Science ®Google Scholar
• Ewer K, Rampling T, Bowyer G, et al. A monovalent chimpanzee adenovirus Ebola vaccine booisted with MVA. N Engl J Med. 2016;374(17):1635–1646.
   PubMed Web of Science ®Google Scholar
• Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16(1):31–42.
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Hensley L, Asiedu C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med. 2011;17(9):1128–1131.
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Martin JE, Graham BS, et al. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol. 2009;7(5):393–400.
   PubMed Web of Science ®Google Scholar
• Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A. 2013;110(5):1893–1898.
   PubMed Web of Science ®Google Scholar
• De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16(3):311–320.
   PubMed Web of Science ®Google Scholar
• Rollier CS, Reyes-Sandoval A, Cottingham MG, et al. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol. 2011;23(3):377–382.
   PubMed Web of Science ®Google Scholar
• Radosevic K, Rodriguez A, Lemckert AAC, et al. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol. 2010;17(11):1687–1694.
   PubMed Web of Science ®Google Scholar
• Rodríguez A, Goudsmit J, Companjen A, et al. Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1. Infect Immun. 2008;76(4):1709–1718.
   PubMed Web of Science ®Google Scholar
• Rodríguez A, Mintardjo R, Tax D, et al. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys. Vaccine. 2009;27(44):6226–6233.
   PubMed Web of Science ®Google Scholar
• Zahn R, Gillisen G, Roos A, et al. Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS One. 2012;7(12):e44115.
   PubMed Web of Science ®Google Scholar
• Milligan ID, Gibani MM, Sewell R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA. 2016;315(15):1610–1623.
   PubMed Web of Science ®Google Scholar
• Zhu F-C, Hou L-H, Li J-X, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. 2015;385(9984):2272–2279.
   PubMed Web of Science ®Google Scholar
• Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States. Clin Diagn Lab Immunol. 2004;11(2):351–357.
   PubMedGoogle Scholar
• Croyle MA, Patel A, Tran KN, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One. 2008;3(10):e3548.
   PubMed Web of Science ®Google Scholar
• Patel A, Zhang Y, Croyle M, et al. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J Infect Dis. 2007;196(Suppl 2):S413–S420.
   PubMed Web of Science ®Google Scholar
• Choi JH, Jonsson-Schmunk K, Qiu X, et al. A single dose respiratory recombinant adenovirus-based vaccine provides long-term protection for non-human primates from lethal Ebola infection. Mol Pharm. 2015;12(8):2712–2731.
   PubMed Web of Science ®Google Scholar
• Peters W, Brandl JR, Lindbloom JD, et al. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans. Vaccine. 2013;31(13):1752–1758.
   PubMed Web of Science ®Google Scholar
• Scallan CD, Tingley DW, Lindbloom JD, et al. An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol. 2013;20(1):85–94.
   PubMed Web of Science ®Google Scholar
• Gilbert SC. Clinical development of modified vaccinia virus Ankara vaccines. Vaccine. 2013;31(39):4241–4246.
   PubMed Web of Science ®Google Scholar
• O’Hara GA, Duncan CJA, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis. 2012;205(5):772–781.
   PubMed Web of Science ®Google Scholar
• Berthoud TK, Hamill M, Lillie PJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011;52(1):1–7.
   PubMed Web of Science ®Google Scholar
• Cottingham MG, Carroll MW. Recombinant MVA vaccines: dispelling the myths. Vaccine. 2013;31(39):4247–4251.
   PubMed Web of Science ®Google Scholar
• Wolferstätter M, Schweneker M, Späth M, et al. Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses. J Virol. 2014;88(24):14396–14411.
   PubMed Web of Science ®Google Scholar
• Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13(11):1267–1277.
   PubMed Web of Science ®Google Scholar
• Sarwar UN, Costner P, Enama ME, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. 2015;211(4):549–557.
   PubMed Web of Science ®Google Scholar
• Kibuuka H, Berkowitz NM, Millard M, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet. 2015;385(9977):1545–1554.
   PubMed Web of Science ®Google Scholar
• Amante DH, Smith TRF, Mendoza JM, et al. Skin transfection patterns and expression kinetics of electroporation-enhanced plasmid delivery using the CELLECTRA-3P, a portable next-generation dermal electroporation device. Hum Gene Ther Methods. 2015;26(4):134–146.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Z, Dai Q. A highly immunogenic fragment derived from Zaire Ebola virus glycoprotein elicits effective neutralizing antibody. Virus Res. 2014;189:254–261.
   PubMed Web of Science ®Google Scholar
• Swenson DL, Warfield KL, Negley DL, et al. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine. 2005;23(23):3033–3042.
   PubMed Web of Science ®Google Scholar
• Lövgren Bengtsson K, Morein B, Osterhaus AD. ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines. 2011;10(4):401–403.
   PubMed Web of Science ®Google Scholar
• Smith G, Raghunandan R, Wu Y, et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One. 2012;7(11):e50852.
   PubMed Web of Science ®Google Scholar
• Bosio CM, Moore BD, Warfield KL, et al. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology. 2004;326(2):280–287.
   PubMed Web of Science ®Google Scholar
• Swenson DL, Warfield KL, Kuehl K, et al. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol. 2004;40(1):27–31.
   PubMedGoogle Scholar
• Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A. 2003;100(26):15889–15894.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Olinger G, Deal EM, et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol. 2005;175(2):1184–1191.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Posten NA, Swenson DL, et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis. 2007;196(Suppl 2):S421–S429.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Demmin G, et al. Filovirus-like particles as vaccines and discovery tools. Expert Rev Vaccines. 2005;4(3):429–440.
   PubMed Web of Science ®Google Scholar
• Martins KAO, Steffens JT, Van Tongeren SA, Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation. PLoS One. 2014;9(2):e89735.
   PubMed Web of Science ®Google Scholar
• Martins KAO, Warren TK, Bavari S. Characterization of a putative filovirus vaccine: virus-like particles. Virol Sin. 2013;28(2):65–70.
   PubMedGoogle Scholar
• Martins K, Carra JH, Cooper CL, et al. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein. Viral Immunol. 2015;28(1):62–70.
   PubMed Web of Science ®Google Scholar
• Martins KAO, Cooper CL, Stronsky SM, et al. Adjuvant-enhanced CD4 T cell responses are critical to durable vaccine immunity. EBioMedicine. 2016;3:67–78.
   PubMed Web of Science ®Google Scholar
• Swenson DL, Warfield KL, Larsen T, et al. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines. 2008;7(4):417–429.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Negley DL, et al. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine. 2004;22(25–26):3495–3502.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Olinger GG, et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis. 2007;196(Suppl 2):S430–S437.
   PubMed Web of Science ®Google Scholar
• Kilgore N, Nuzum EO. An interagency collaboration to facilitate development of filovirus medical countermeasures. Viruses. 2012;4(10):2312–2316.
   PubMed Web of Science ®Google Scholar
• Bradfute SB. Duration of immune responses after Ebola virus vaccination. Lancet Infect Dis. 2016;16(1):2–3.
   PubMed Web of Science ®Google Scholar
• Patel M, Shane AL, Parashar UD, et al. Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis. 2009;200(Suppl 1):S39–S48.
   PubMed Web of Science ®Google Scholar
• Qadri F, Bhuiyan TR, Sack DA, et al. Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine. 2013;31(3):452–460.
   PubMed Web of Science ®Google Scholar
• Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. 2010;8:129.
   PubMed Web of Science ®Google Scholar
• Qiu X, Fernando L, Alimonti JB, Mucosal immunization of Cynomolgus macaques with the VSVΔG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS One. 2009;4(5):e5547.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008;26(52):6894–6900.
   PubMed Web of Science ®Google Scholar
• Pratt WD, Wang D, Nichols DK, et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol. 2010;17(4):572–581.
   PubMed Web of Science ®Google Scholar